TH9507

DRUG2 trials

Sponsors

Theratechnologies

Conditions

HIV InfectionsLipodystrophyType 2 Diabetes

Phase 2

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

CompletedNCT01264497

TheratechnologiesType 2 Diabetes

Start: 2002-02-28End: 2002-11-30Updated: 2010-12-21

Phase 3

TH9507 in Patients With HIV-Associated Lipodystrophy

CompletedNCT00123253

TheratechnologiesHIV Infections, Lipodystrophy

Start: 2005-06-30End: 2007-04-30Updated: 2013-11-27

Related Papers

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

PLoS ONE2017-06-1515 citations

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

2012-04-1023 citations

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

2007-12-01133 citations